Skip to Content

Travivo Approval Status

Travivo (gepirone extended-release) is an investigational azapirone antidepressant in development for the treatment of adults with major depressive disorder.

Development Status and FDA Approval Process for Travivo

DateArticle
Mar 17, 2016FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder
Dec  2, 2015Fabre-Kramer Looks Forward to FDA's Decision on Gepirone ER for the Treatment of Major Depressive Disorder
Nov  5, 2007Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
May  8, 2007Fabre-Kramer Refiles Gepirone ER with the FDA for the Treatment of Major Depressive Disorder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide